Neoadjuvant liposomal doxorubicin and carboplatin is effective and tolerable for the treatment of early stage triple negative breast cancer

被引：0
|
作者：
Chan, Nancy
Lu, Shou-en
Wang, Yue
Riedlinger, Gregory M.
Omene, Coral
George, Mridula
Malhotra, Jyoti
Kowzun, Maria
Eladoumikdachi, Firas G.
Potdevin, Lindsay B.
Kumar, Shicha
Matsuda, Kant
Desai, Shruti
Patel, Nayana
Toppmeyer, Deborah L.
Ganesan, Shridar
Hirshfield, Kim
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P2-12-15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-12-15
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Enhancing triple-negative breast cancer treatment: sulforaphane-doxorubicin liposomal formulation for targeted therapy and chemoprotection
    Pogorzelska, A.
    Medynska, K.
    Mazur, M.
    Switalska, M.
    Wietrzyk, J.
    Milczarek, M.
    Wiktorska, K.
    FEBS OPEN BIO, 2024, 14 : 310 - 310
  • [32] Neoadjuvant phase II trial with eribulin and carboplatin in patients with triple-negative breast cancer
    Giordano, Sara Barnato
    Rao, Shreyas
    Hamdan, Randala
    Jeruss, Jacqueline
    Bethke, Kevin
    Hansen, Nora
    Khan, Seema
    Von Roenn, Jamie
    Rosen, Steven
    Gradishar, William J.
    Siziopikou, Kalliopi
    Meservey, Caitlin
    Kaklamani, Virginia
    MOLECULAR CANCER RESEARCH, 2013, 11
  • [33] Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial
    Schneeweiss, Andreas
    Moebus, Volker
    Tesch, Hans
    Hanusch, Claus
    Denkert, Carsten
    Luebbe, Kristina
    Huober, Jens
    Klare, Peter
    Kuemmel, Sherko
    Untch, Michael
    Kast, Karin
    Jackisch, Christian
    Thomalla, Joerg
    Ingold-Heppner, Barbara
    Blohmer, Jens-Uwe
    Rezai, Mahdi
    Frank, Matthias
    Engels, Knut
    Rhiem, Kerstin
    Fasching, Peter Andreas
    Nekljudova, Valentina
    von Minckwitz, Gunter
    Loibl, Sibylle
    EUROPEAN JOURNAL OF CANCER, 2019, 106 : 181 - 192
  • [34] Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
    Lee, Jin Sun
    Yost, Susan E.
    Yuan, Yuan
    CANCERS, 2020, 12 (06)
  • [35] Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy
    Marra, Antonio
    Curigliano, Giuseppe
    CANCER JOURNAL, 2021, 27 (01): : 41 - 49
  • [36] Novel Neoadjuvant Treatment Strategies for Triple-Negative Breast Cancer
    Davis, Andrew A.
    Gradishar, William J.
    ONCOLOGY-NEW YORK, 2020, 34 (05): : 176 - +
  • [37] Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer
    Snider, Jessica N.
    Young, Robyn R.
    Schwartzberg, Lee Steven
    Allen, Jeffrey Warren
    Javed, Yasir Ahmed
    Jahanzeb, Mohammad
    Sachdev, Jasgit C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] State of the art treatment for neoadjuvant/adjuvant triple negative breast cancer
    Carey, L. A.
    CANCER RESEARCH, 2021, 81 (04)
  • [39] Controversial issues in the neoadjuvant treatment of triple-negative breast cancer
    Fitzpatrick, Amanda
    Tutt, Andrew
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [40] Substituting Doxorubicin with Nonpegylated Liposomal Doxorubicin for the Treatment of Early Breast Cancer: Results of a Retrospective Study
    Davidson, Neville
    Camburn, Teresa
    Keary, Ian
    Houghton, David
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2014, 2014
12345